Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2037-12-01
Target enrollment:
Participant gender:
Summary
Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in
mRCC. However, the optimal schedule of the combination therapy has yet to be defined.
The objective of the trial is to determine the efficacy of combination immunotherapy of
nivolumab and ipilimumab in patients with metastatic renal cell carcinoma.
The expansion phase shall address the role of ipilimumab in case of clinically insignificant
progression.